Evidence map›Paper›PMID 38472720›Full record

ReviewIn vitro cellular & developmental biology. Animal2024

Secondary Publication: Proposal for Points of Consideration for Pluripotent Stem Cell Culture.

Takashi Aoi, Isao Asaka, Hidenori Akutsu, Yuzuru Ito, Ken Kataoka, Yasunari Kanda, Hajime Kojima, Yuko Sekino, Hirofumi Suemori, Masato Nakagawa and 6 more

Abstract readReview
In one paragraph

Review in In vitro cellular & developmental biology. Animal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Takashi AoiDivision of Stem Cell Medicine, Graduate School of Medicine, Kobe University, Kobe, Hyogo, 650-0017, Japan.
Isao AsakaDepartment of Fundamental Cell Technology, Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan.
Hidenori AkutsuCenter for Regenerative Medicine, National Center for Child Health and Development, Tokyo, 157-8538, Japan.
Yuzuru ItoFaculty of Life and Environmental Sciences (Bioindustrial Sciences), University of Tsukuba, Tsukuba, Ibaraki, 305-8972, Japan.
Ken KataokaDepartment of Life Science, Faculty of Science, Okayama University of Science, Okayama, 700‑0005, Japan.
Yasunari KandaDivision of Pharmacology, National Institute of Health Sciences, Kawasaki, Kanagawa, 210-0821, Japan.
Hajime KojimaJapanese Center for the Validation of Alternative Methods, National Institute of Health Sciences, Kawasaki, Kanagawa, 210-0821, Japan.
Yuko SekinoGraduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-Ku, Tokyo, 113-8657, Japan.
Hirofumi SuemoriDivision of Clinical Basis for ES Cell Research, Institute for Frontier Life and Medical Sciences, Center for Human ES Cell Research, Kyoto University, 53 Kawahara-Cho, Shogoin, Sakyo-Ku, Kyoto, 606-8507, Japan.
Masato NakagawaDepartment of Life Science Frontiers, Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan.
Kazuaki NakamuraDepartment of Pharmacology, National Research Institute for Child Health and Development, Tokyo, 157-8535, Japan.
Yukio NakamuraCell Engineering Division, RIKEN BioResource Research Center, Tsukuba, 305-0074, Japan.
Makiko FujiiDepartment of Genomic Oncology and Oral Medicine, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, 834-8553, Japan.
Miho FurueLaboratory of Stem Cell Cultures, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, 567-0085, Japan. mkfurue@gmail.com.ORCID http://orcid.org/0000-0001-5032-9953
Daiju YamazakiDivision of Pharmacology, National Institute of Health Sciences, Kawasaki, Kanagawa, 210-0821, Japan.
Japanese Working Group for Consideration of Good Cell Culture Practice

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human pluripotent stem cells, such as human embryonic stem cells and human induced pluripotent stem cells, are used in basic research and various applied fields, including drug discovery and regenerative medicine. Stem cell technologies have developed rapidly in recent years, and the supply of culture materials has improved. This has facilitated the culture of human pluripotent stem cells and has enabled an increasing number of researchers and bioengineers to access this technology. At the same time, it is a challenge to share the basic concepts and techniques of this technology among researchers and technicians to ensure the reproducibility of research results. Human pluripotent stem cells differ from conventional somatic cells in many aspects, and many points need to be considered in their handling, even for those experienced in cell culture. Therefore, we have prepared this proposal, "Points of Consideration for Pluripotent Stem Cell Culture," to promote the effective use of human pluripotent stem cells. This proposal includes seven items to be considered and practices to be confirmed before using human pluripotent stem cells. These are laws/guidelines and consent/material transfer agreements, diversity of pluripotent stem cells, culture materials, thawing procedure, media exchange and cell passaging, freezing procedure, and culture management. We aim for the concept of these points of consideration to be shared by researchers and technicians involved in the cell culture of pluripotent stem cells. In this way, we hope the reliability of research using pluripotent stem cells can be improved, and cell culture technology will advance.

Indexed as

Cell Culture TechniquesPluripotent Stem CellsCryopreservationCulture MediaHumansCulture MediaCell cultureDiversityGood Cell Culture PracticePluripotent stem cell

Identifiers

PMID38472720
PMCPMC11126491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.